Karen G Potter

Title: Innovations of Karen G. Potter in Immunology

Introduction

Karen G. Potter is a notable inventor based in San Diego, California. She has made significant contributions to the field of immunology, particularly in understanding the mechanisms of T cell activation. Her work has implications for therapeutic strategies in various diseases.

Latest Patents

Karen G. Potter holds a patent for "Compositions and methods for modulating responses mediated or associated with BTLA activity." This patent focuses on the Herpesvirus entry mediator (HVEM), which is a member of the tumor necrosis factor receptor superfamily. HVEM acts as a molecular switch that modulates T cell activation by propagating positive signals or inhibitory signals. The patent discloses a novel binding site for BTLA located in cysteine-rich domain-1 of HVEM. This binding site overlaps with the binding site for the Herpes Simplex virus-1 envelope glycoprotein D, yet is distinct from where LIGHT binds. Additionally, the patent identifies a BTLA activating protein present in human cytomegalovirus known as UL144, which inhibits T cell proliferation.

Career Highlights

Karen G. Potter is affiliated with the La Jolla Institute for Allergy and Immunology, where she conducts her research. Her work has been instrumental in advancing the understanding of immune responses and their modulation.

Collaborations

Karen has collaborated with notable colleagues such as Carl F. Ware and Carl De Trez, contributing to the advancement of immunological research.

Conclusion

Karen G. Potter's innovative work in immunology, particularly her patent on BTLA activity modulation, showcases her significant contributions to the field. Her research continues to influence therapeutic approaches in immunology.